Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of RSV Vaccine LYB005 in Adults
NCT06904222Phase 1Active, not recruiting
- Sponsor
- Patronus Biotech
- Start
- Apr 2025
- Primary completion
- Aug 2026
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LYB005 in respiratory syncytial virus infection (RSV) (7 arms), sponsored by Patronus Biotech. Primary endpoints: Occurrence of immediate adverse events at 30 months, Incidence of solicited AE and 3 more. Started Apr 2025; status: active, not recruiting.
02
Drugs
LYB005
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06904222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06904222.